Literature DB >> 24247133

Efficacy of three-week oxytetracycline or rifampin monotherapy compared with a combination regimen against the filarial nematode Onchocerca ochengi.

Germanus S Bah1, Emma L Ward, Abhishek Srivastava, Alexander J Trees, Vincent N Tanya, Benjamin L Makepeace.   

Abstract

Onchocerciasis (river blindness), caused by the filarial nematode Onchocerca volvulus, is a major cause of visual impairment and dermatitis in sub-Saharan Africa. As O. volvulus contains an obligatory bacterial symbiont (Wolbachia), it is susceptible to antibiotic chemotherapy, although current regimens are considered too prolonged for community-level control programs. The aim of this study was to compare the efficacies of oxytetracycline and rifampin, administered separately or in combination, against a close relative of O. volvulus (Onchocerca ochengi) in cattle. Six animals per group were treated with continuous or intermittent oxytetracycline regimens, and effects on adult worm viability, dermal microfilarial loads, and Wolbachia density in worm tissues were assessed. Subsequently, the efficacies of 3-week regimens of oxytetracycline and rifampin alone and a combination regimen were compared, and rifampin levels in plasma and skin were quantified. A 6-month regimen of oxytetracycline with monthly dosing was strongly adulticidal, while 3-week and 6-week regimens exhibited weaker adulticidal effects. However, all three regimens achieved >2-log reductions in microfilarial load. In contrast, rifampin monotherapy and oxytetracycline-rifampin duotherapy failed to induce substantive reductions in either adult worm burden or microfilarial load, although a borderline effect on Wolbachia density was observed following duotherapy. Dermal rifampin levels were maintained above the MIC for >24 h after a single intravenous dose. We conclude that oxytetracycline-rifampin duotherapy is less efficacious against O. ochengi than oxytetracycline alone. Further studies will be required to determine whether rifampin reduces oxytetracycline bioavailability in this system, as suggested by human studies using other tetracycline-rifampin combinations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24247133      PMCID: PMC3910861          DOI: 10.1128/AAC.01995-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

2.  Comparison of the serum pharmacokinetics of a long acting and a conventional oxytetracycline injection.

Authors:  L A Davey; M T Ferber; B Kaye
Journal:  Vet Rec       Date:  1985-10-26       Impact factor: 2.695

Review 3.  Rifamycins--obstacles and opportunities.

Authors:  Paul A Aristoff; George A Garcia; Paul D Kirchhoff; H D Showalter
Journal:  Tuberculosis (Edinb)       Date:  2010-03-16       Impact factor: 3.131

4.  Molecular systematics of five Onchocerca species (Nematoda: Filarioidea) including the human parasite, O. volvulus, suggest sympatric speciation.

Authors:  R Morales-Hojas; R A Cheke; R J Post
Journal:  J Helminthol       Date:  2006-09       Impact factor: 2.170

5.  Antibiotics and Wolbachia in filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi.

Authors:  S Townson; D Hutton; J Siemienska; L Hollick; T Scanlon; S K Tagboto; M J Taylor
Journal:  Ann Trop Med Parasitol       Date:  2000-12

6.  Doxycycline and rifampicin for mild scrub-typhus infections in northern Thailand: a randomised trial.

Authors:  G Watt; P Kantipong; K Jongsakul; P Watcharapichat; D Phulsuksombati; D Strickman
Journal:  Lancet       Date:  2000-09-23       Impact factor: 79.321

7.  No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin.

Authors:  Frank O Richards; Josef Amann; Byron Arana; George Punkosdy; Robert Klein; Carlos Blanco; Beatriz Lopez; Carlos Mendoza; Alfredo Domínguez; Jeannette Guarner; James H Maguire; Mark Eberhard
Journal:  Am J Trop Med Hyg       Date:  2007-11       Impact factor: 2.345

8.  Observations on the reproductive biology of Onchocerca volvulus.

Authors:  H Schulz-Key
Journal:  Acta Leiden       Date:  1990

9.  Characteristics of persons who complied with and failed to comply with annual ivermectin treatment.

Authors:  William R Brieger; Joseph C Okeibunor; Adenike O Abiose; Richard Ndyomugyenyi; Samuel Wanji; Elizabeth Elhassan; Uche V Amazigo
Journal:  Trop Med Int Health       Date:  2012-05-11       Impact factor: 2.622

10.  Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic-tandem mass spectrometric method.

Authors:  Abhishek Srivastava; David Waterhouse; Alison Ardrey; Stephen A Ward
Journal:  J Pharm Biomed Anal       Date:  2012-06-01       Impact factor: 3.935

View more
  6 in total

1.  Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis.

Authors:  Lisa Luu; Germanus S Bah; Ndode Herman Okah-Nnane; Catherine S Hartley; Alexandra F Glover; Tessa R Walsh; Lu-Yun Lian; Bin Zhan; Maria Elena Bottazzi; David Abraham; Nikolai Petrovsky; Nicolas Bayang; Bernard Tangwa; Rene Billingwe Ayiseh; Glory Enjong Mbah; David D Ekale; Vincent N Tanya; Sara Lustigman; Benjamin L Makepeace; John Graham-Brown
Journal:  Vaccines (Basel)       Date:  2022-05-27

2.  Doxycycline Leads to Sterility and Enhanced Killing of Female Onchocerca volvulus Worms in an Area With Persistent Microfilaridermia After Repeated Ivermectin Treatment: A Randomized, Placebo-Controlled, Double-Blind Trial.

Authors:  Alexander Yaw Debrah; Sabine Specht; Ute Klarmann-Schulz; Linda Batsa; Sabine Mand; Yeboah Marfo-Debrekyei; Rolf Fimmers; Bettina Dubben; Alexander Kwarteng; Mike Osei-Atweneboana; Daniel Boakye; Arcangelo Ricchiuto; Marcelle Büttner; Ohene Adjei; Charles D Mackenzie; Achim Hoerauf
Journal:  Clin Infect Dis       Date:  2015-05-06       Impact factor: 9.079

3.  Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model.

Authors:  Sabine Specht; Kenneth M Pfarr; Sandra Arriens; Marc P Hübner; Ute Klarmann-Schulz; Marianne Koschel; Sonja Sternberg; Coralie Martin; Louise Ford; Mark J Taylor; Achim Hoerauf
Journal:  PLoS Negl Trop Dis       Date:  2018-01-04

Review 4.  Advances in Antiwolbachial Drug Discovery for Treatment of Parasitic Filarial Worm Infections.

Authors:  Malina A Bakowski; Case W McNamara
Journal:  Trop Med Infect Dis       Date:  2019-07-18

Review 5.  Development of emodepside as a possible adulticidal treatment for human onchocerciasis-The fruit of a successful industrial-academic collaboration.

Authors:  Jürgen Krücken; Lindy Holden-Dye; Jennifer Keiser; Roger K Prichard; Simon Townson; Benjamin L Makepeace; Marc P Hübner; Steffen R Hahnel; Ivan Scandale; Achim Harder; Daniel Kulke
Journal:  PLoS Pathog       Date:  2021-07-22       Impact factor: 6.823

Review 6.  Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives.

Authors:  Wan Aliaa Wan Sulaiman; Joseph Kamtchum-Tatuene; Mohd Hazmi Mohamed; Vasudevan Ramachandran; Siew Mooi Ching; Sazlyna Mohd Sazlly Lim; Hasnur Zaman Hashim; Liyana Najwa Inche Mat; Fan Kee Hoo; Hamidon Basri
Journal:  Indian J Med Res       Date:  2019-06       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.